alpha-methylhydrocinnamic acid has been researched along with rosiglitazone in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, B; Fu, L; Jia, J; Li, L; Liu, J; Mei, C; Shen, J; Tang, J; Wang, L; Xiong, X; Ye, Y | 1 |
| Chen, M; Dai, B; Fu, L; Liu, M; Mei, C; Shen, J; Tang, J; Wang, L; Wang, Q; Xiong, X; Ye, Y | 1 |
| Fu, L; Gao, X; Hu, H; Jia, J; Li, L; Mei, C; Shen, J; Wang, L; Xiong, X; Ye, Y | 1 |
3 other study(ies) available for alpha-methylhydrocinnamic acid and rosiglitazone
| Article | Year |
|---|---|
Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; L-Lactate Dehydrogenase; Phenylpropionates; PPAR gamma; Propidium; Rosiglitazone; Thiazolidinediones | 2009 |
Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Mice; Mice, Nude; Models, Chemical; Phenylpropionates; PPAR gamma; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Xenograft Model Antitumor Assays | 2010 |
Antitumor efficacy of two novel non-thiazolidinedione compounds as peroxisome proliferator-activated receptor-gamma agonists in human osteosarcoma cells in vitro.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Osteosarcoma; Phenylpropionates; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2009 |